Drug Development Pipeline
Restore CFTR Function
FDL169 is a new CFTR corrector. Correctors are drugs designed to fix and restore the function of the defective CFTR protein. The corrected CFTR then moves to the cell surface, where it functions as a chloride channel and helps maintain the right balance of fluid in the airways.
A study to test the safety of this compound on those with two copies of the F508del CFTR mutation is underway in Europe.
This program is sponsored by Flatley Discovery Lab. It is being conducted within the Therapeutics Development Network.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More